Intranasal drug delivery: How, why and what for?

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 12, Issue 3, 2009, Pages 288-311

  Pires, Anaísa ^a,b   Fortuna, Ana ^a,b   Alves, Gilberto ^b,c   Falcão, Amílcar ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIHISTAMINIC AGENT; CHITOSAN; CORTICOSTEROID; CYCLODEXTRIN; ENZYME INHIBITOR; EXCIPIENT; FENTANYL; INFLUENZA VACCINE; INSULIN; LEVODOPA; LEVONORGESTREL; LIPOSOME; METOCLOPRAMIDE; METOPROLOL; MICROSPHERE; NANOPARTICLE; NIFEDIPINE; PRODRUG; PROGESTERONE; PROPRANOLOL;

BLOOD BRAIN BARRIER; BLOOD FLOW; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSPORT; ENZYMATIC DEGRADATION; HUMAN; LIPOPHILICITY; MOLECULAR WEIGHT; MUCOADHESION; MUCOCILIARY CLEARANCE; NONHUMAN; NOSE CAVITY; OLFACTORY SYSTEM; PH; RESPIRATORY FUNCTION; REVIEW; RHINOSINUSITIS; VACCINATION; VISCOSITY; ABSORPTION; ANIMAL; BIOAVAILABILITY; DRUG DEVELOPMENT; HISTOLOGY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NOSE MUCOSA; PHYSIOLOGY;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DISCOVERY; HUMANS; NASAL CAVITY; NASAL MUCOSA;

EID: 77950358719     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3nc79     Document Type: Review

References (171)

1. Stoner CL, Cleton A, Johnson K, Oh DM, Hallak H, Brodfuehrer J, Surendran N, Han HK. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. Int J Pharm, 2004; 269:241-249.
2. Hou T, Wang J, Zhang W, Xu X. ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J Chem Inf Model, 2007; 47:208-218.
3. Dressman JB, Thelen K, Jantratid E. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet, 2008; 47:655-667.
4. Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control Release, 2003; 87:187-198.
5. Yamaya M, Finkbeiner WE, Chun SY, Widdicombe JH. Differentiated structure and function of cultures from human tracheal epithelium. Am J Physiol, 1992; 262:L713-L724.
6. Romeo VD, Meireles J, Sileno AP, Pimplaskar HK, Behl CR. Effects of physicochemical properties and other factors on systemic nasal delivery. Adv Drug Deliv Rev, 1998; 29:89-116.
7. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today, 2002; 7:1184-1189.
8. Graff LC, Pollock GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci, 2005; 94:1187-1195.
9. Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Costantino HR. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm, 2007; 335:138-146.
10. Mygind N, Dahl R. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev, 1998; 29:3-12.
11. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today, 2002; 7:967-975.
12. Rapoport A, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache, 2006; 46:S192-S201.
13. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm, 2007; 337:1-24.
14. Hosoya K, Kubo H, Natsume H, Sugibayashi K, Morimoto Y. Evaluation of enhancers to increase nasal absorption using Ussing chamber technique. Biol Pharm Bull, 1994; 17:316-322.
15. Kaliner MA. A novel and effective approach to treating rhinitis with nasal antihistamines. Ann Allergy Asthma Immunol, 2007; 99:383-390.
16. Costantino HR, Leonard AK, Brandt G, Johnson PH, Quay SC. Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci, 2008; 9:S3-S6.
17. Gupta S, Moulik SP. Biocompatible microemulsions and their prospective uses in drug delivery. J Pharm Sci, 2008; 97:22-45.
18. Jogani V, Jinturkar K, Vyas T, Misra A. Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul, 2008; 2:25-40.
19. Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous systems and treat neurodegenerative disease. BMC Neurosci, 2008; 9:S3-S5.
20. Shelley K, Paech MJ. The clinical applications of intranasal opioids. Curr Drug Deliv, 2008; 5:55-58.
21. Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv, 2008; 5:1159-1168.
22. Mann JF, Acevedo R, Campo JD, Pérez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev Vaccines, 2009; 8:103-112.
23. Wermeling DP. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics, 2009; 6:352-358.
24. Dekker M., Encyclopedia of Pharmaceutical Technology. Informa HealthCare, New York, USA, 2002.
25. Chien YW, Chang SF. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst, 1987; 4:67-194.
26. Wynsberghe D.V., Noback R.C., Carola R., Human anatomy and physiology, McGraw-Hill Companie, UK, 1994.
27. Stevens A., Lowe J., Human histology, Mosby, Philadelphia, USA, 1997.
28. Merkus FW, Verhoef JC, Schipper NG, Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev, 1998; 29:13-38.
29. Agu, R.U., Ugwoke, M.I., Drug Absorption Studies:In situ, In vitro and In silico models, chapter 5, Springer, USA, 2007.
30. Kimbell JS, Gross EA, Richardson RB, Conolly RB, Morgan KT. Correlation of regional formaldehyde flux predictions with the distribution of formaldehyde-induced squamous metaplasia in F344 rat nasal passages. Mutat Res, 1997; 380:143-154.
31. Gosau M, Rink D, Driemel O, Draenert FG. Maxillary sinus anatomy: a cadaveric study with clinical implications. Anat Rec, 2009; 292:352-354.
32. Dondeti P, Zia H, Needham TE. Bioadhesive and formulation parameters affecting nasal absorption. Int J Pharm, 1996; 127:115-133.
33. Verdugo P. Goblet cells secretion and mucogenesis Annu Rev Physiol, 1990; 52:157-176.
34. Lethem MI. The role of tracheobronchial mucus in drug administration to the airways. Adv Drug Deliv, 1993; 11:19-27.
35. Dae-Duk Ki, Drug Absorption Studies: In situ, In vitro and In silico models, chapter 9, Springer, USA, 2007.
36. Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev Vaccines, 2008; 7:1257-1276.
37. Charlton S, Jones NS, Davis SS, Illum L. Distribution and clearance of bioadhesive formulations from the olfactory region in man: Effect of polymer type and nasal delivery device. Eur J Pharm Sci, 2007; 30:295-302.
38. Wattanakumtornkul S, Pinto AB, Williams DB. Intranasal hormone replacement therapy. Menopause, 2003; 10:88-98.
39. Martindale: The complete drug reference (http://www.medicinescomplete.com/mc/mart indale/2007)
40. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf, 2003; 26:863-893.
41. Desrosiers MY, Salas-Prato M. Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: Results of a controlled trial. Otolaryngol Head Neck Surg, 2001; 125:265-269.
42. Vaughan WC, Carvalho G. Use of nebulized antibiotics for acute infections in chronic sinusitis. Otolaryngol Head Neck Surg, 2002; 127:558-568.
43. Ramadan HH, Sanclement JA, Thomas JG. Chronic rhinosinusitis and biofilms. Otolaryngol Head Neck Surg, 2005; 132:414-417.
44. Sanderson AR, Leid JG, Hunsaker D. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope, 2006; 116:1121-1126.
45. Desrosiers M, Bendouah Z, Barbeau J. Effectiveness of topical antibiotics on Staphylococcus aureus biofilm in vitro. Am J Rhinol, 2007; 21:149-153.
46. Lim M, Citardi MJ, Leong JL. Topical antimicrobials in the management of chronic rhinosinusitis: A systematic review. Am J Rhinol, 2008; 22:381-389.
47. Furubayashi T, Kamaguchi A, Kawaharada K, Masaoka Y, Kataoka M, Yamashita S, Higashi Y, Sakane T. Evaluation of the Contribution of the Nasal Cavity and Gastrointestinal Tract to Drug Absorption Following Nasal Application to Rats. Biol Pharm Bull, 2007; 30:608-611.
48. Ding WX, Qi XR, Fu Q, Piao HS. Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. Drug Deliv, 2007; 14:101-104.
49. Heidari A, Sadrai H, Varshosaz J. Nasal delivery of insulin using bioadhesive chitosan gels. Drug Deliv, 2006; 13:31-38.
50. Ugwoke MI, Kaufmann G, Verbeke N, Kinget R. Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. Int J Pharm, 2000; 202:125-131.
51. Stoke DG, Reber KR, Waltzman LS, Erns C, Hamilton D, Gawareck D, Mermelstein F, McNicol E, Wright C, Carr DB. Analgesic efficacy and safety of morphine-chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med, 2008; 9:3-12.
52. Kilian N, Müller DG. The effect of a viscosity and an absorption enhancer on the intra nasal absorption of metoprolol in rats. Int J Pharm, 1998; 163:211-217.
53. Patil SB, Sawant KK. Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery. J Microencapsul, 2008; 9:1-12.
54. Rathnam G, Narayanan N, Ilavarasan R. Carbopol-based gels for nasal delivery of progesterone. AAPS Pharm Sci Tech, 2008; 9:1078-1082.
55. Yu S, Zhao Y, Wu F, Zhang X, Lü W, Zhang H, Zhang Q. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm, 2004; 281:11-23.
56. Varshosaz J, Sadrai H, Heidari A. Nasal delivery of insulin using bioadhesive chitosan gels. Drug Deliv, 2006; 13:31-38.
57. Wang J, Tabata Y, Morimoto K. Aminated gelatin microspheres as a nasal delivery system for peptide drugs: Evaluation of in vitro release and in vivo insulin absorption in rats. J Control Release, 2006; 113:31-37.
58. Karasulu E, Yavasoǧlu A, Evrensanal Z, Uyanikgil Y, Karasulu HY. Permeation studies and histological examination of sheep nasal mucosa following administration of different nasal formulations with or without absorption enhancers. Drug Deliv, 2008; 15:219-225.
59. Onischuk AA, Tolstikova TG, Sorokina IV. Anti-inflammatory effect from indomethacin nanoparticles inhaled by male mice. J Aerosol Med Pulm Drug Deliv, 2008; 21:231-243.
60. Leykin Y, Casati A, Rapotec A. A prospective, randomized, double-blind comparison between parecoxib and ketorolac for early postoperative analgesia following nasal surgery. Minerva Anestesiol, 2008; 74:475-479.
61. Moodie JE, Brown CR, Bisley EJ. The safety and analgesic efficacy of intranasal ketorolac in patients with postoperative pain. Anesth Analg., 2008; 107:2025-2031.
62. Shao Z, Park GB, Krishnamoorthy R, Mitra AK. The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2'-ester prodrugs. Pharm Res, 1994; 11:237-242.
63. Yang C, Gao H, Mitra AK. Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir. J Pharm Sci, 2001; 90:617-624.
64. Alsarra IA, Hamed AY, Alanazi FK. Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. Drug Deliv, 2008; 15:313-321.
65. Alsarra IA, Hamed AY, Mahrous GM, El Maghraby GM, Al-Robayan AA, Alanazi FK. Mucoadhesive polymeric hydrogels for nasal delivery of Acyclovir. Drug Dev Ind Pharm, 2009; 35:352-62.
66. Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ, Mikszta JA, Sullivan VJ. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine, 2004; 23:794-801.
67. Sharma S, Mukkur TKS, Benson HA, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci, 2009; 98:812-43.
68. Slutter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J Drug Target, 2008; 16:1-17.
69. Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L. Safety and immunogenicity of a Proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine, 2006; 24:1601-1608.
70. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine, 2005; 23:1029-1036.
71. Drabick JJ, Brandt BL, Moran EE, Saunders NB, Shoemaker DR, Zollinger WD. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine, 2000; 18:160-172.
72. Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus in infants and young children. J Infect Dis, 2004; 190:2096-2103.
73. Greenberg DP, Walker RE, Min-Shi L, Reisinger KS. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis, 2005; 191:1116-1122.
74. Brave A, Hallengard D, Schroder U, Blomberg P, Wahren B, Hinkula J. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses. Vaccine, 2008; 26:5075-5078.
75. Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, Junginger HE. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm, 2008; 69:405-416.
76. Graff CL, Zhao R, Pollack GM. Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation. Pharm Res, 2005; 22:235-244.
77. Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv, 2005; 2:165-175.
78. Pardrige WM. Blood brain barrier biology and methodology. J Neurovirol, 1999; 5:5556-5569.
79. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 2000; 11:1-18.
80. Graff CL, Pollack GM. P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res, 2003; 20:1225-1230.
81. Graff CL, Pollack GM. Functional Evidence for P-glycoprotein at the Nose-Brain Barrier. Pharm Res, 2005; 22:86-93.
82. Westin U, Piras E, Jansson B, Bergström U, Dahlin M, Brittebo E, Björk E. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci, 2005; 24:565-573.
83. Thorne RG, Pronk GJ, Padmanabhan V, Frey II WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2005; 127:481-496.
84. Chow HH, Anavy N, Villalobos A. Direct Nose-Brain Transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci, 2001; 90:1729-1735.
85. Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm, 2003; 255:87-97.
86. Zhang QZ, Jiang XG, Wu CH. Distribution of nimodipine in brain following intranasal administration in rats. Acta Pharmacol Sin, 2004; 25:522-527.
87. Doyle KP, Yang T, Lessov NS, Ciesielski TM, Stevens SL, Simon RP, King JS, Stenzel-Poore MP. Nasal administration of osteopotin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab, 2008; 28:1235-1248.
88. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Nose-to-brain delivery of tacrine. J Pharm Pharmacol, 2007; 59:1199-1205.
89. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord, 2008; 22:116-124.
90. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey 2nd WH, Deen DF. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol, 2008; 10:112-120.
91. Sakane T, Yamashita S, Yata N, Sezaki H. Transnasal delivery of 5-fluorouracil to the brain in the rat. J Drug Target, 1999; 7:233-240.
92. Barakat NS, Omar SA, Ahmed AA. Carbamazepine uptake into rat brain following intra-olfactory transport. J Pharm Pharmacol, 2006; 58:63-72.
93. Yamada K, Hasegawa M, Kametani S, Ito S. Nose-to-brain delivery of TS-002, prostaglandin D2 analogue. J Drug Target, 2007; 15:59-66.
94. Van den Berg MP, Merkus P, Romeijn SG, Verhoef JC, Merkus FW. Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparation with a human study. Pharm Res, 2004; 21:799-802.
95. Van den Berg MP, Verhoef JC, Romeijn SG, Merkus FW. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm, 2004; 58:131-135.
96. Yang Z, Huang Y, Gan G, Sawchuk RJ. Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats. J Pharm Sci, 2005; 94:1577-1588.
97. Kaur P, K Kim. Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. Int J Pharm, 2008; 364:27-35.
98. Illum L, Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J Pharm Sci, 2007; 96:473-483.
99. McMartin C. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci, 1987; 76:535-540.
100. Huang CH, Kimura R, Nassar RB, Hussain A. Mechanism of nasal absorption of drugs. I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J Pharm Sci, 1985; 74:608-611.
101. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res, 2000; 17:978-984.
102. Schipper N, Verhoef J, Merkus FW. The nasal mucociliary clearance: Relevance to nasal drug delivery. Pharm Res, 1991; 8:807-814.
103. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance in health and disease. Eur Respir J, 1999; 13:1177-1188.
104. Afzelius B. A, The lung: Scientific Foundations, Lippincott-Raven, Philadelphia, 1997.
105. Bogdanffy MS. Biotransformation enzymes in the rodent nasal mucosa: The value of a histochemical approach. Environ Health Perspect, 1990; 85:177-186.
106. Dahl AR, Lewis JL. Respiratory tract uptake of inhalants and metabolism of xenobiotics. Annu Rev Pharmacol Toxicol, 1993; 33:383-407.
107. Mitra AK, Krishnamoorthy R. Prodrugs for nasal drug delivery. Adv Drug Deliv Rev, 1998; 29:135-146.
108. Dimova S, Brewster ME, Noppe M, Jorissen M, Augustijns P. The use of human nasal in vitro cell systems during drug discovery and development. Toxicol In Vitro, 2005; 19:107-122.
109. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res, 1992; 9:1-9.
110. Lee VH, Yamamoto A. Penetration and enzymatic barriers of peptide and protein absorption. Adv Drug Deliv Rev, 1990; 4:171-207.
111. Harris AS. Intranasal administration of peptides: nasal deposition, biological response and absorption of desmopressin. J Pharm Sci, 1986; 75:1085-1088.
112. Kandimalla KK, Donovan MD. Transport of hydroxyzine and triprolidine across bovine olfactory mucosa: role of passive diffusion in the direct nose-to-brain uptake of small molecules. Int J Pharm, 2005; 302:133-144.
113. Christrup LL, Foster D, Popper LD. Pharmacokinetics, Efficacy, and Tolerability of Fentanyl Following Intranasal Versus Intravenous Administration in Adults Undergoing Third-Molar Extraction: A Randomized, Double-Blind, Double-Dummy, Two-Way, Crossover Study. Clin Ther, 2008; 30:469-481.
114. Corbo DC. Characterization of the barrier properties of mucosal membranes. J Pharm Sci, 1990; 79:202-206.
115. Donovan M, Flynn G, Amidon G. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res, 1990; 7:863-868.
116. Fisher A, Illum L, Davis S, Schacht E. Diiodo-L-tyrosine labelled dextrans as molecular size markers of nasal absorption in the rat. J Pharm Pharmacol, 1992; 44:550-554.
117. Katdare A., Chaubal M.V., Excipient Development for Pharmaceutical Biotechnology and Drug Delivery Systems. Taylor & Francis Group, LLC, USA, 2006.
118. Corbo DC. Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm Res, 1989; 6:848-852.
119. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf, 2000; 23:11-33.
120. Washington N, Steele RJ, Jackson SJ, Bush D, Mason J, Gill DA, Pitt K, Rawlins DA. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm, 2000; 198:139-146.
121. Hirai S, Yashiki T, Matsuzawa T, Mima H. Absorption of drugs from the nasal mucosa of rats. Int J Pharm, 1981; 7:317-325.
122. Hussain A.A., Bawarshi-Nassar R., Huang C.H., Transnasal Systemic Medications. Elsevier, Amsterdam, 1985.
123. Zaki NM, Awad GA, Mortada ND, Abd ElHady SS. Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part I. Influence of formulation variables on drug absorption in anesthetized rats. Int J Pharm, 2006; 327:89-96.
124. Machida M. Effects of surfactants and protease inhibitors on nasal absorption of recombinant human granulocyte colonystimulating factor (rhG-CSF) in rats. Biol Pharm Bull, 1994; 17:1375-1378.
125. Morimoto K, Miyazaki M, Kakemi M. Effects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats. Int J Pharm, 1995; 113:1-8.
126. Bernkop-Schnurch A. Use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release, 1998; 52:1-16.
127. Hussain AA, Al-Bayatti AA, Dakkuri A, Okochi K, Hussain MA. Testosterone 17β-N, N-Dimethylglycinate Hydrochloride: A prodrug with a potential for nasal delivery of testosterone. J Pharm Sci, 2002; 91:785-789.
128. Pujara CP, Shao Z, Duncan MR, Mitra AK. Effects of formulation variables on nasal epithelial cell integrity: Biochemical evaluations. Int J Pharm, 1995; 114:197-203.
129. Albert A. Chemical aspects of selective toxicity. Nature, 1958; 182:421-430.
130. Higuchi T., Stella V., Prodrugs as Novel Drug Delivery Systems, American Chemical Society, Washington, DC, 1975.
131. Wang H, Hussain AA, Wedlund PJ. Nipecotic Acid: Systemic availability and brain delivery after nasal administration of nipecotic acid and n-Butyl nipecotate to rats. Pharm Res, 2005; 22:556-562.
132. Hussain MA. The use of alpha-aminoboronic acid derivatives to stabilize peptide drugs during their intranasal absorption. Pharm Res, 1989; 6:186-189.
133. Hoang VD, Uchenna AR, Mark J, Renaat K, Norbert V. Characterization of human nasal primary culture systems to investigate peptide metabolism. Int J Pharm, 2002; 238:247-256.
134. O'Hagan DT. Nasal absorption enhancers for biosynthetic human growth hormone in rats. Pharm Res, 1990; 7:772-776.
135. Greimel A, Bernkop-Schnürch A, Del Curto MD, D'Antonio M. Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa. Drug Dev Ind Pharm, 2007; 33:71-77.
136. Hersey SJ, Jackson RT. Effect of bile salts on nasal permeability in vitro. J Pharm Sci, 1987; 76:876-879.
137. Mishima M, Wakita Y, Nakano M. Studies on the promoting effects of medium chain fatty acid salts on the nasal absorption of insulin in rats. J Pharmacobiodyn, 1987; 10:624-631.
138. Baglioni C, Phipps RJ. Nasal absorption of interferon: enhancement by surfactant agents. J Interferon Res, 1990; 10:497-504.
139. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res, 1994; 11:1186-1189.
140. Ekelund K, Osth K, Påhlstorp C, Björk E, Ulvenlund S, Johansson F. Correlation between epithelial toxicity and surfactant structure as derived from the effects of polyethylynyoxide surfactants on caco-2 monolayers and pig nasal mucosa. J Pharm Sci, 2005; 94:730-44.
141. Sinswat P, Tengamnuay P. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl-and dimethyl-β-cyclodextrins. Int J Pharm, 2003; 257:15-22.
142. Zaki NM, Mortada ND, Awad GA, Abd ElHady SS. Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm, 2006; 327:97-103.
143. Giunchedi P, Juliano C, Gavini E, Cossu M, Sorrenti M. Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug loaded chitosan microspheres. Eur J Pharm Biopharm, 2002; 53:233-239.
144. Maestrelli F, Zerrouk N, Chemto C, Mura P. Influence of chitosan and its glutamate and hydrochloride salts on naproxen dissolution rate and permeation across Caco-2 cells. Int J Pharm, 2004; 271:257-267.
145. Ravi Kumar MNV, Muzzarelli RAA, Muzzarelli C, Sashiwa H, Domb AJ. Chitosan chemistry and pharmaceutical perspectives. Chem Rev, 2004; 104:6017-6084.
146. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev, 1998; 98:1743-1754.
147. Duchêne D, Bochot A, Yu SC, Pépin C, Seiller M. Cyclodextrins and emulsions. Int J Pharm, 2003; 266:85-90.
148. Asai K, Morishita M, Katsuta H, Hosoda S, Shinomiya K, Noro M, Nagai T, Takayama K. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int J Pharm, 2002; 246:25-35.
149. Babu RJ, Dayal P, Singh M. Effect of cyclodextrins on the complexation and nasal permeation of melatonin. Drug Deliv, 2008; 15:381-388.
150. Jug M, Becirevic-Lacan M. Development of a Cyclodextrin-Based Nasal Delivery System for Lorazepam. Drug Dev Ind Pharm, 2008; 34:817-826.
151. Merkus FW, Verhoef JC, Marttin E, Romeijn SG, Van der Kuy PH, Hermens WA, Schipper NG. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev, 1999; 36:41-57.
152. Gavini E, Rassu G, Sanna V, Cossu M, Giunchedi P. Mucoadhesive microspheres for nasal administartion of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies. J Pharm Pharmacol, 2005; 57:287-294.
153. Gavini E, Rassu G, Haukvik T, Lanni C, Racchi M, Giunchedi P. Mucoadhesive microspheres for nasal administration of cyclodextrins. J Drug Target, 2008; 17:168-179.
154. Patil SB, Sawant KK. Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery. J Microencapsul, 2008; iFirst:1-12.
155. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev, 2005; 57:1640-1665.
156. Jain AK, Chalasani KB, Khar RK, Ahmed FJ, Diwan PV. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target, 2007;15:417-427.
157. Law SL, Huang KJ, Chou VHY, Cherng JY. Enhancement of nasal absorption of calcitonin loaded in liposomes. J Liposome Res, 2001; 11:164-174.
158. Murramatsu K, Maitani Y, Takayama K, Nagai T. The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with an enhancer containing insulin in rabbits. Drug Dev Ind Pharm, 1999; 25:1099-1105.
159. Kato Y, Hosokawa T, Hayakawa E, Ito K. Influence of liposomes on tryptic digestion of insulin. Biol Pharm Bull, 1993; 16:457-461.
160. Lee VH, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst, 1991; 8:91-192.
161. Vyas SP, Goswami SK, Singh R. Liposomes based nasal delivery system of nifedipine: Development and characterization. Int J Pharm, 1995; 118:23-30.
162. Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G, Karlsen J, Giunchedi P. Nasal administration of Carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int J Pharm, 2006; 307:9-15.
163. Tiyaboonchai W. Chitosan Nanoparticles: A Promising System for Drug Delivery. Naresuan University Journal, 2003; 11:51-66.
164. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res, 1999; 16:1576-1581.
165. Fernandez-Urrusuno R, Romani D, Calvo P, Vila-Jato JL, Alonso MJ. Development of a freeze dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. S.T. P Pharma Sciences, 1999; 9:429-436.
166. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, Smith A, Illum L. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res, 2002; 19:998-1008.
167. Mao S, Germershaus O, Fischer D, Linn T, Schnepf R, Kissel T. Uptake and transport of PEG-graft-trimethyl-chitosan copolymerinsulin nanocomplexes by epithelial cells. Pharm Res, 2005; 22:2058-2068.
168. Simon M, Wittmar M, Kissel T, Linn T. Insulin containing nanocomplexes formed by self assembly from biodegradable aminemodified poly(vinyl alcohol)-graft-poly(Llactide): Bioavailability and nasal tolerability in rats. Pharm Res, 2005; 22:1879-1886.
169. Jung T, Kamm W, Breitenbach A, Hungerer KL, Hundt E, Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): Evaluation of antibody response after oral and nasal application in mice. Pharm Res, 2001; 18:352-360.
170. Debin A, Kravtzoff R, Vaz Santiago J, Cazales L, Sperandino S, Melber K, Janowics Z, Betbeder D, Moynier M. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine, 2002; 20:2752-2763.
171. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosancoated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res, 2004; 21:671-674.